China Immunodiagnostics business Acquired | Healthcare M&A Deal

Revvity, Inc. has announced the divestiture of China Immunodiagnostics business, a diagnostics imaging business in China, for about $711 million. The China Immunodiagnostics business provides immunodiagnostic testing products and services that support clinical laboratory workflows and diagnostic imaging use cases. Revvity is separating the China unit, which generated roughly 6% of fiscal 2025 revenue, to refocus its healthcare diagnostics portfolio. The healthcare M&A divestiture is structured as a letter of intent with a prospective buyer, with a definitive agreement expected in Q2 2026 and completion targeted for 2027 after regulatory approvals.